I am a
Home I AM A Search Login

Papers of the Week

2021 Dec 24

J Thorac Oncol

A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.


Cho B C, Han J-Y, Kim S-W, Lee K H, Cho E K, Lee Y-G, Kim D-W, Kim J-H, Lee G-W, Lee J-S, Shim B Y, Kim J-S, Chun S H, Lee S S, Kim H R, Hong M H, Ahn J S, Sun J-M, Lee Y J, Lee D H, et al.
J Thorac Oncol. 2021 Dec 24.
PMID: 34958928.


This integrated analysis of a phase 1/2 study (NCT03046992) assessed the efficacy and safety of lazertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), in patients with advanced EGFR T790M-positive non-small cell lung cancer (NSCLC) after prior EGFR TKI therapy.